Physician profile
Jignesh P Modi
NPI 1184935074
$923.55
in general payments reported to CMS, 2019-2025
23 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $13.43 · 2021: $276 · 2022: $17.67 · 2023: $50.45 · 2024: $58.56 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $137.79 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $86.60 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $67.94 | 2023-2025 | Ingrezza, Ongentys |
| Mallinckrodt Hospital Products INC. | $61.58 | 2025 | Acthar |
| Allergan, INC. | $60.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $58.65 | 2019 | |
| Insmed, INC. | $46.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $44.82 | 2019 | |
| Melinta Therapeutics, LLC | $43.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $43.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.77 | 2019 | |
| Janssen Biotech, INC. | $32.16 | 2019 | |
| Csl Behring | $26.37 | 2024 | Hizentra |
| Baxter Healthcare | $23.58 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $23.56 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.74 | 2021 | |
| Neurelis, INC. | $16.70 | 2024 | Valtoco |
| Alexion Pharmaceuticals, INC. | $16.21 | 2019 | |
| Ucb, INC. | $16.02 | 2023 | Nayzilam |
| Regeneron Healthcare Solutions, INC. | $15.57 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.49 | 2024 | Voquezna |
| Advanced Respiratory, INC | $15.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.91 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jignesh Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.